| Somatotropin deficiency

Ngenla vs Genotropin

Side-by-side clinical, coverage, and cost comparison for somatotropin deficiency.

Deep comparison between: Ngenla vs Genotropin with Prescriber.AI

AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.

Safety signalsGenotropin has a higher rate of injection site reactions vs Ngenla based on FDA-approved prescribing information

Coverage gaps3 major payers require step therapy for Genotropin but not Ngenla, including UnitedHealthcare

Category

Ngenla

Genotropin

At A Glance

RouteSC injection

FrequencyOnce weekly

ClassGrowth hormone analog

RouteSC injection

Frequency6-7 times weekly

ClassRecombinant human growth hormone

Indications

Somatotropin deficiency

Somatotropin deficiency
Prader-Willi Syndrome
Growth failure
Turner Syndrome
Growth Disorders

Dosing

Somatotropin deficiency 0.66 mg/kg based on actual body weight administered SC once weekly; individualize dosage based on growth response. When switching from daily growth hormone, initiate NGENLA on the day following the last daily injection.

Somatotropin deficiency (pediatric) 0.16 to 0.24 mg/kg/week SC, divided into 6-7 subcutaneous injections.

Prader-Willi Syndrome 0.24 mg/kg/week SC, divided into 6-7 subcutaneous injections.

Turner Syndrome 0.33 mg/kg/week SC, divided into 6-7 subcutaneous injections.

Growth Disorders Up to 0.47 mg/kg/week SC (idiopathic short stature), divided into 6-7 subcutaneous injections.

Growth failure Up to 0.48 mg/kg/week SC (born small for gestational age), divided into 6-7 subcutaneous injections.

Somatotropin deficiency (adult) Non-weight based: starting ~0.2 mg/day SC (range 0.15-0.30 mg/day), titrated by 0.1-0.2 mg/day increments; weight based: starting up to 0.04 mg/kg/week SC, titrated to up to 0.08 mg/kg/week.

Contraindications

Acute critical illness after open heart surgery, abdominal surgery, multiple accidental trauma, or acute respiratory failure
Hypersensitivity to somatrogon-ghla or any excipient in NGENLA
Closed epiphyses
Active malignancy
Active proliferative or severe non-proliferative diabetic retinopathy
Prader-Willi syndrome with severe obesity, history of upper airway obstruction or sleep apnea, or severe respiratory impairment

Acute critical illness due to complications following open heart surgery, abdominal surgery, multiple accidental trauma, or acute respiratory failure
Prader-Willi syndrome with severe obesity, history of upper airway obstruction or sleep apnea, or severe respiratory impairment
Active malignancy
Known hypersensitivity to somatropin or any excipient
Active proliferative or severe non-proliferative diabetic retinopathy
Closed epiphyses (for growth promotion in pediatric patients)

Drug Interactions

674View drug interactions

267View drug interactions

Adverse Reactions

Most common (>=5%) Injection site reactions, nasopharyngitis, headache, pyrexia, anemia, cough, vomiting, hypothyroidism, abdominal pain, rash, oropharyngeal pain

Serious Increased mortality in acute critical illness, severe hypersensitivity, increased risk of neoplasm, glucose intolerance and diabetes mellitus, intracranial hypertension, fluid retention, hypoadrenalism, hypothyroidism, slipped capital femoral epiphysis, progression of preexisting scoliosis, pancreatitis, lipoatrophy, sudden death in pediatric patients with Prader-Willi syndrome

Postmarketing Osteonecrosis in pediatric patients

Most common (>=5%) Peripheral swelling, arthralgia, upper respiratory infection, pain in extremities, peripheral edema, paresthesia, headache, stiffness of extremities, fatigue (reported in adult GHD clinical trials at or above 5% threshold)

Serious Increased mortality in acute critical illness, fatalities in Prader-Willi syndrome, neoplasms, glucose intolerance and diabetes mellitus, intracranial hypertension, severe hypersensitivity, fluid retention, hypoadrenalism, hypothyroidism, slipped capital femoral epiphysis, scoliosis progression, otitis media and cardiovascular disorders in Turner syndrome, pancreatitis

Postmarketing Serious systemic hypersensitivity reactions including anaphylaxis and angioedema, leukemia, new-onset type 2 diabetes mellitus, slipped capital femoral epiphysis, osteonecrosis/avascular necrosis, carpal tunnel syndrome

Pharmacology

Somatrogon-ghla is a human growth hormone analog that binds to the GH receptor and activates the STAT5b signaling pathway, increasing serum IGF-1 concentrations and stimulating linear growth and metabolic changes in pediatric patients with growth hormone deficiency.

Somatropin, a recombinant human growth hormone therapeutically equivalent to pituitary-derived GH, stimulates linear growth in pediatric patients through effects on epiphyseal plates, normalizes IGF-I concentrations in GHD and Prader-Willi syndrome, and in adults reduces fat mass and increases lean body mass with favorable lipid metabolic changes.

View Full FDA Information

View full FDA information

Enter your patient's insuranceCheck specific coverage details for your patient.

Most Common Insurance

Anthem BCBS

Ngenla